Pfizer Stock Executives


USD 44.08  0.49  1.10%   

Pfizer employes about 79 K people. The company is managed by 46 executives with total tenure of roughly 277 years, averaging almost 6.0 years of service per executive having 1717.39 employees per reported executive. Evaluation of Pfizer management performance can provide insight into the firm performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Pfizer Inc future performance.
Please check Your Equity Center.
  Ian Read  Chairman
Chairman, CEO and Chairman of Executive Committee
  John Young  President
Group President - Pfizer Innovative Health and Angela Hwang
  Frank DAmelio  President
Chief Financial Officer, Executive Vice President - Business Operations and Global Supply

Pfizer Management Team Effectiveness

Pfizer Inc has Return on Asset of 13.19 % which means that on every $100 spent on asset, it made $13.19 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 37.4 %, implying that it generated $37.4 on every 100 dollars invested. Pfizer management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.

Pfizer Workforce Comparison

Pfizer Inc is considered to be number one stock in number of employees category among related companies. The total workforce of Drug Manufacturers—General industry is at this time estimated at about 79,126. Pfizer totals roughly 79,000 in number of employees claiming about 100% of equities under Drug Manufacturers—General industry.

Pfizer Profit Margins

The company has Net Profit Margin of 28.94 %, which may imply that it executes well on its competitive polices and has reasonable control over its expenses and variable costs. This is very large. In the same way, it shows Net Operating Margin of 37.61 %, which entails that for every 100 dollars of revenue, it generated 0.38 of operating income.

Pfizer Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pfizer insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pfizer's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Pfizer insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Pfizer Inc Benchmark Summation

The output start index for this execution was three with a total number of output elements of fifty-eight. The Indexes of lowest and highest values over a specified period line shows minimum and maximum index of Pfizer Inc price series.

Pfizer Notable Stakeholders

A Pfizer stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Pfizer often face trade-offs trying to please all of them. Pfizer's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Pfizer's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Ian Read - Chairman, CEO and Chairman of Executive CommitteeProfile
John Young - Group President - Pfizer Innovative Health and Angela HwangProfile
Frank DAmelio - Chief Financial Officer, Executive Vice President - Business Operations and Global SupplyProfile
Douglas Lankler - Executive Vice President General CounselProfile
Dawn Rogers - Chief Human Resource Officer, Executive Vice PresidentProfile
Mikael Dolsten - Chief Scientific Officer, President - Worldwide Research, Development and MedicalProfile
Lidia Fonseca - Executive Vice President, Chief Technology Officer and Digital OfficerProfile
Alexander Mackenzie - Executive Vice President Chief Development OfficerProfile
Geno Germano - Group President of Global Innovative Pharma Bus.Profile
Laurie Olson - Executive Vice President - Strategy, Portfolio and Commercial OperationsProfile
Sally Susman - Chief Corporate Affairs Officer, Executive Vice PresidentProfile
Anthony Maddaluna - Executive Vice President and Presidentident - Pfizer Global SupplyProfile
Freda LewisHall - Executive Vice President Chief Medical OfficerProfile
Rady Johnson - Chief Compliance, Quality and Risk Officer, Executive Vice PresidentProfile
Charles Hill - Executive Vice President - Worldwide Human ResourcesProfile
Albert Bourla - Group President - Vaccines, Oncology and Consumer Healthcare BusinessProfile
Payal Sahni - Executive Vice President, Chief People Experience OfficerProfile
Kirsten LundJurgensen - Executive Vice President and Presidentident - Pfizer Global SupplyProfile
Angela Hwang - Group President - Pfizer Biopharmaceuticals GroupProfile
Kathrin Jansen - Senior Vice President - Vaccine Research & DevelopmentProfile
Michael Goettler - Group President - Pfizer UpjohnProfile
Helen Hobbs - Independent DirectorProfile
Shantanu Narayen - Lead Independent DirectorProfile
James Smith - Independent DirectorProfile
Dennis Ausiello - Independent DirectorProfile
Susan DesmondHellmann - Independent DirectorProfile
Frances Fergusson - Independent DirectorProfile
Stephen Sanger - Independent DirectorProfile
Wyllie Cornwell - Independent DirectorProfile
Suzanne Johnson - Independent DirectorProfile
Susan Hockfield - Independent DirectorProfile
Dan Littman - Independent DirectorProfile
James Kilts - Independent DirectorProfile
Don Cornwell - Independent DirectorProfile
James Quincey - Independent DirectorProfile
Joseph Echevarria - Independent DirectorProfile
Scott Gottlieb - Independent DirectorProfile
Ronald Blaylock - Independent DirectorProfile
Jennifer Damico - Senior Vice President Principal Accounting Officer, ControllerProfile
Michael Mcdermott - Executive Vice President Chief Global Supply OfficerProfile
Gordon Loh - Senior Vice President Corporate AuditProfile
Aamir Malik - Executive Vice President Chief Business Innovation OfficerProfile
Christopher Stevo - Senior Vice President and Chief Investor Relations OfficerProfile
William Gray - Independent DirectorProfile
William Carapezzi - Executive Vice President - Global Business Services and TransformationProfile
Mike Mcdermott - Executive Vice President Chief Global Supply OfficerProfile

About Pfizer Management Performance

The success or failure of an entity such as Pfizer Inc often depends on how effective the management is. Pfizer management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Pfizer management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Pfizer management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 79000 people.
The data published in Pfizer's official financial statements usually reflect Pfizer's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Pfizer Inc. For example, before you start analyzing numbers published by Pfizer accountants, it's critical to develop an understanding of what Pfizer's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Pfizer's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pfizer's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Pfizer's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pfizer Inc. Please utilize our Beneish M Score to check the likelihood of Pfizer's management to manipulate its earnings.

Pfizer Workforce Analysis

Traditionally, organizations such as Pfizer use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Pfizer within its industry.

Pfizer Manpower Efficiency

Return on Pfizer Manpower

Revenue Per Employee1.3 M
Revenue Per Executive2.2 B
Net Income Per Employee373.2 K
Net Income Per Executive640.9 M
Working Capital Per Employee182.3 K
Working Capital Per Executive313.2 M
Please check Your Equity Center. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Complementary Tools for Pfizer Stock analysis

When running Pfizer Inc price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Bond Directory
Find actively traded corporate debentures issued by US companies
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Transaction History
View history of all your transactions and understand their impact on performance
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine Pfizer value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.